Europe PMC
open access
Influence of oncogenic drivers and signaling pathways on immune checkpoint inhibitor efficacy in NSCLC
Non-small cell lung cancer (NSCLC) is characterized by intricate genetic modifications and mechanisms that allow it to evade immune detection, which complicates the pursuit of lasting therapeutic responses. The effectiveness of treatments is greatly affected by the interaction between tumor genetic
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Evaluation System for the Efficacy of Immunologic Checkpoint Inhibitors in NSCLC#321712
- cDC1 Prognostic and Predictive Role in Non-Small-Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors#834443
- Immune Response to Immunotherapy in Lung Cancer: Study of Sputum and Blood Samples#812848
- Radiotherapy in patients with NSCLC developing progressive disease during immune checkpoint inhibition : : abscopal responses and survival#1106691
- Ponatinib in Advanced NSCLC w/ RET Translocations#1140055
Record · ID 1015719
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive